Abstract
Polyamidoamine (PAMAM) dendrimer is emerging as an effective nanocarrier for delivering anticancer drugs. Still, unmodified PAMAM dendrimer is hardly used in vivo because of unsatisfied drug release, high tendency of interfering with cellular membranes, and rapid clearance by reticuloendothelial system. In this study, low generation polyamidoamine (PAMAM) dendrimer G3.0 is developed and surface modified with methoxypolyethylene glycol (PAMAM G3.0-mPEG) to overcome its limitations. Specifically, PAMAM G3.0 conjugated with mPEG at different ratios are investigated to effectively eliminate its charge-associated toxicity, in which PAMAM G3.0-mPEG- 8 is chosen for oxaliplatin (OX) loading. Results reveal that OX-loaded PAMAM G3.0-mPEG-8 has desirable size, good entrapment efficiency, and sustained release with minimum drug leakage. In addition, Resazurin assay indicates that the toxicity of loaded OX is reduced as compared to free drug but still maintain substantially anticancer activity on HeLa cells, suggesting the potential application of PAMAM G3.0-mPEG-8 for OX delivery in cancer therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
